Abstract: The present invention relates to process and intermediates for the preparation of substituted 1,3-oxathiolanes. The present invention specifically relates to a process for the preparation of lamivudine.

Abstract: Processes for preparing pure tiagabine, a piperidine carboxylic acid, using pharmaceutically acceptable acid addition salts of tiagabine esters are provided. L(+)-tartaric acid, oxalic acid and dibenzoyl L(+)-tartaric acid addition salts of tiagabine esters are also provided. Further, processes for preparing acid addition salts of tiagabine esters are provided.

Abstract: The present invention relates to controlled release formulations comprising lamotrigine and process for preparation thereof.

Abstract: The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors.

Abstract: The present invention relates to duloxetine salts having enantiomeric purity of 98% or more and a process for such salts.

Abstract: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

Abstract: The present invention relates to a packaging kit used for the stabilization of sirolimus particles wherein the packaging kit is in the form of a vacuum sealed impermeable container. It further relates to a method for stabilization of sirolimus particles as well as composition comprising the particles.

Abstract: The present invention relates to extended release tablets comprising a core which comprises of nisoldipine, a rate-controlling hydrophilic polymer and optionally, an enteric agent. Such tablets may also be coated with a release rate-controlling coating comprising of a hydrophobic polymer or enteric agent or combinations thereof, in particular ethylcellulose, and Eudragits.

Abstract: The present invention relates to a process for the preparation of cis-intermediates of Formula II, (Formula II) wherein R1 represents hydrogen, (un)substituted alkyl, alkenyl, aryl, and X represents a leaving group, which are useful synthetic intermediates in the preparation of tetracyclic compounds having phosphodiesterase inhibitory activity.

Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

Abstract: The present invention relates to isoxazoline derivatives of structure Ia, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CNS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type IV inhibitors.

Abstract: The present invention relates to a process for the preparation of pantoprazol sodium sesquihydrate of formula (I) and pantoprazole sodium.

Abstract: The present invention relates to a bilayered tablet comprising: a slow release layer comprising niacin and release retarding agent; and an immediate release layer comprising HMG-CoA reductase inhibitor.

Abstract: This invention relates to stabilized pharmaceutical compositions comprising atorvastatin or pharmaceutically acceptable salts thereof, and processes for the preparation of the same.

Abstract: The present invention discloses modified-release oral dosage forms of an azabicyclo derivative or its pharmaceutically acceptable salts, solvates, esters, enantiomers, diastereomers, N-oxides and polymorphs; and processes for the preparation thereof. The modified release formulation comprises an azabicyclo derivative, at least one rate-controlling polymer and at least one pharmaceutically acceptable excipient which provides therapeutically effective plasma levels of the active ingredient for a period of up to 24 hours.

Abstract: The present invention relates to polymorphic forms of milnacipran hydrochloride. The polymorphic forms are designated as Form (I), Form (II), Form (III), Form (IV) and Form V of milnacipran hydrochloride. The present invention also relates to processes for the preparation of the polymorphic forms.

Abstract: The present invention relates to an extended release tablet formulation comprising niacin and a release retarding agent selected from hydroxypropyl cellulose, polyethylene oxide or mixtures thereof.

Abstract: The present invention relates to standardized extracts of Boerhaavia diffusa, wherein the extracts have anti inflammatory and analgesic activities. The present invention also includes bioassay guided fractionation of Boerhaavia diffusa leading to the identification of bioactive markers; processes for the isolation of the bioactive markers; processes for the preparation of the extracts enriched with bioactive markers from Boerhaavia diffusa; pharmaceutical compositions comprising bioactive markers, or standardized extracts of Boerhaavia diffusa and methods of standardization of the extracts.

Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.

Abstract: The present invention relates to processes for the preparation of Type I, Type II and Type III crystals of prulifloxacin.